October 2, 2015 — AstraZeneca announced that Brilinta (ticagrelor) 60-mg tablets are now available in U.S. pharmacies. On Sept. 3, 2015, the U.S. Food and Drug Administration (FDA) approved a new 60-mg dosage strength for Brilinta to be used in patients with a history of heart attack beyond the first year.
The medication is approved to reduce the rate of cardiovascular (CV) death, myocardial infarction (MI) and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, Brilinta is superior to clopidogrel.
The dosing of Brilinta in the management of ACS is 90 mg twice daily during the first year after an ACS event. After one year, patients with a history of heart attack can now be treated with 60 mg twice daily. The medication must be used with a daily maintenance dose of aspirin of 75-100mg.
For more information: www.brilinta.com